Anastasiou Peter 4

What Happened

Peter Anastasiou, Chief Operating Officer of Harmony Biosciences Holdings, was granted a derivative award covering 212,241 shares, reported on Form 4 for the transaction dated 2026-04-02. The filing reports an acquisition at $0.00 (this reflects a granted option/award rather than an open-market purchase or sale). The grant is compensation-related and not an outright market purchase.

Key Details

• Transaction date: 2026-04-02; Form 4 filed with the SEC on 2026-04-06.
• Transaction type: Award/Grant (derivative) of 212,241 shares; acquisition price shown as $0.00.
• Shares owned after transaction: not specified in the information provided.
• Footnote on vesting: 25% of the underlying shares vest on April 2, 2027; the remainder vests ratably on a quarterly basis through the fourth anniversary of the grant, subject to continued service.
• No indication in this summary that shares were immediately sold or that this was a cashless exercise.

Context

This was a compensation grant (stock-option-style award) rather than a market purchase or sale. Such awards are common for executives and are tied to continued service; they do not necessarily signal a personal buy or sell decision. The reported $0.00 acquisition price reflects the nature of the grant on the Form 4, not a cash purchase price paid on the open market.